Mounjaro Guide
Mounjaro is the brand-name formulation of tirzepatide FDA-approved for type 2 diabetes in adults and children 10 and older, and to reduce major cardiovascular events in high-risk adults with type 2 diabetes, manufactured by Eli Lilly. It is prescribed weekly by injection and has become extremely popular off-label for weight loss given its superior efficacy data. The weight-management indication for tirzepatide belongs to its sister brand, Zepbound.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
At a Glance
| Generic Name | Tirzepatide |
| Brand Names | Mounjaro |
| FDA Status | FDA-approved for type 2 diabetes in adults (May 2022), extended to pediatric patients aged 10+ (December 2025), and approved to reduce major adverse cardiovascular events in high-risk adults with type 2 diabetes (August 2026). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).[1] |
| Approval Date | May 13, 2022[1] |
How Mounjaro Works
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon. The same pathways simultaneously reduce appetite, slow gastric emptying, and appear to act directly on fat cells — producing the highest weight loss rates of any approved medication.[2][3]
Dosing Schedule
Mounjaro uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea (12–18%), diarrhea (12–17%), vomiting (5–9%), constipation (6–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.[1][2]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
In the SURPASS-2 trial, Mounjaro (tirzepatide 15mg) reduced HbA1c by 2.46 percentage points and produced 12.4 lbs more weight loss than semaglutide 1mg. Sub-analyses showed 41% of participants achieved an HbA1c below 5.7% — essentially normal blood sugar levels.[2]
Where to Get Mounjaro
These telehealth providers offer access to tirzepatide with online consultations and home delivery. Before you book a consult, our guide to getting Mounjaro online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.
Editorial score · methodology
Maximus
Best for: men seeking compounded tirzepatide alongside testosterone optimization
Editorial score · methodology
SkinnyRx
Best for: compounded semaglutide or tirzepatide with the consult and free overnight shipping in one price
Editorial score · methodology
Editorial score · methodology
Vytora Health
Best for: compounded or brand-name GLP-1 with named pharmacy partners, 50 states
Editorial score · methodology
Pallas Health
Best for: the most complete public disclosure of pharmacies and prescribing physicians we have found
Editorial score · methodology
Cost Comparison
Each provider's lowest ongoing monthly cash price for Mounjaro, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose.
| Provider | From (ongoing) | |
|---|---|---|
| Sesame Care | $499/mostarting dose | Visit |
| Vital Edge | $835/mo | Visit |
| Maximus | $1,250/mostarting dose | Visit |
| WePeptideRx | $1,250/moper 4 weeks | Visit |
| Bon Health | $1,269/mo+ added fee | Visit |
| Effecty | $1,300/mosee plan details | Visit |
| Pallas Health | $1,349/mosee plan details | Visit |
| DudeMeds | $1,350/mo3-month plan rate | Visit |
| Vytora Health | $1,399/mo | Visit |
| SkinnyRx | $1,400/mosee plan details | Visit |
| Corsica Health | $1,499/mosee plan details | Visit |
| Layla | $1,499/moafter intro offer | Visit |
| myRocky | $1,509/mo | Visit |
| Hers | $1,899/mo+ required membership | Visit |
| Hims | $1,899/mo+ required membership | Visit |
Mounjaro Head-to-Head Comparisons
Short-form verdict pages comparing Mounjaro to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.
See all drug-vs-drug verdicts, or compare every weight loss medication we cover.
Mounjaro Patient Questions, Answered
Real patient questions about Mounjaro pulled from named subreddits and answered with peer-reviewed trial data.
Mounjaro Reference Cards
Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.
Ranked PubMed Studies on Mounjaro
Curated lists of the highest-impact peer-reviewed studies on Mounjaro and related GLP-1 drugs. Every PMID is checked against its PubMed record.
Related Research on Mounjaro
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Frequently Asked Questions
Sources & methodology (as of November 2026)
- 1.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
- 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Tirzepatide · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism